922727-65-9
Chemical Structure
Pantoprazole-d6
Synonym(s): BY1023-d6;SKF96022-d6
- CAS No.: 922727-65-9
- Formula:C16H9D6F2N3O4S
- Molecular Weight:389.41
IUPAC Name: potassium (2S,3S,4R,5R)-2-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis(sulfonatooxy)tetrahydro-2H-pyran-2-yl)oxy)-2,5-bis((sulfonatooxy)methyl)tetrahydrofuran-3,4-diyl bis(sulfate)
InChIKey: IQPSEEYGBUAQFF-WFGJKAKNSA-N
SMILES: O=S(C1=NC2=CC=C(OC(F)F)C=C2N1)CC3=NC=CC(OC([2H])([2H])[2H])=C3OC([2H])([2H])[2H]
Biological Activity: Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pantoprazole-d6 | Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pantoprazole (Standard) | 99.77% | Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pantoprazole-d3 | Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pantoprazole-d8 | Pantoprazole-d8 (BY1023-d8) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pantoprazole-d4 | Pantoprazole-d4 (BY1023-d4) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pantoprazole | 99.95% | Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [3]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [Content Brief]
- [4]. W Beil, et al. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71. [Content Brief]
